BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• BioMidwest

  BioVigil Raises Growth Funding Round to Accelerate Success

  BioVigil has raised growth funding to accelerate success and scale the business.

  April 6, 2022

   · 

  2 min read
• BioMidwest

  Oral Vaccine Boosts COVID Immunity

  Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2.

  April 6, 2022

   · 

  3 min read
• Business

  Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress

  Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders.

  April 6, 2022

   · 

  13 min read
• Business

  Nevro to Report First Quarter 2022 Financial Results

  Company to Host Conference Call on Wednesday, May 4, 2022 at 1:30 pm PT / 4:30 pm ET.

  April 6, 2022

   · 

  2 min read
• Drug Development

  Lutris Pharma Completes Enrollment of Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Patients with Breast Cancer

  Lutris Pharma today announced that it has completed enrollment of part two of its phase 1/2 clinical trial of lead compound, LUT014.

  April 6, 2022

   · 

  4 min read
• Genetown

  Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 06, 2022

  Epizyme announced that the Company has granted equity awards to Jerald Korn, the Company’s Chief Operating Officer, with a grant date of April 1, 2022, as equity inducement awards outside of the Company’s 2013 Stock Incentive Plan and material to Mr. Korn’s acceptance of employment with the Company.

  April 6, 2022

   · 

  1 min read
• Genetown

  AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 06, 2022

  AVROBIO, Inc. announced that the company has granted a non-statutory stock option for the purchase of up to 22,000 shares of the company’s common stock to one employee as an inducement award under the company’s 2019 Inducement Plan.

  April 6, 2022

   · 

  5 min read
• Business

  Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie

  Alvotech Holdings S.A. has today announced the resolution of all intellectual property disputes with AbbVie in Europe and selected markets outside of Europe, related to its AVT02 biosimilar candidate.

  April 6, 2022

   · 

  13 min read
• Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference

  Silence Therapeutics plc today announced that the Company will present at the 21st Annual Needham Virtual Healthcare Conference at 8:00 a.m. Eastern Time on Thursday, April 14, 2022.

  April 6, 2022

   · 

  1 min read
• Drug Development

  ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks

  ULTOMIRIS ® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks.

  April 6, 2022

   · 

  15 min read